Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions. Its lead candidate, NXP900, is an orally administered small-molecule inhibitor of the SRC and YES1 kinases, licensed worldwide from the University of Edinburgh. The company… From the company’s description.
In fiscal 2025, Nuvectis Pharma, Inc. reported a net loss of $26.44M. Operations used $16.01M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nuvectis Pharma, Inc. does
In the company’s own words
Nuvectis Pharma, Inc. (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions. Its lead candidate, NXP900, is an orally administered small-molecule inhibitor of the SRC and YES1 kinases, licensed worldwide from the University of Edinburgh. The company is evaluating NXP900 in a Phase 1b clinical study as a single agent in selected tumor types and in combination with EGFR and ALK inhibitors. Nuvectis has no commercial products and reports no revenue. It also licensed NXP800, a small-molecule cancer drug candidate, but ceased its clinical development in 2025 after completing a Phase 1b study. The company focuses its development and business-development activities on building a pipeline of oncology drug candidates; it does not describe reportable business segments. Nuvectis relies on third-party manufacturers to produce NXP900 for clinical trials and had 13 full-time employees at the time of the report. The company was incorporated as Centry Pharma in 2020 and adopted the Nuvectis Pharma name in 2021. Its website is www.nuvectis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FORT LEE, NJ
- Fiscal year end
- December
- CIK
- 1875558
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nuvectis Pharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nuvectis Pharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nuvectis Pharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nuvectis Pharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nuvectis Pharma, Inc.'s last four quarterly filings that the numbers alone won't show?”